According to Boston Scientific, the Taxus Liberte is the only second-generation drug-eluting stent available in Japan. Design improvements over the company’s first-generation Taxus Express2 stent include thinner struts to allow better stent deliverability and conformability, as well as uniform stent geometry for consistent lesion coverage and drug distribution.
Maulik Nanavaty, president of Boston Scientific Japan, said: “We are very pleased to launch Taxus Liberte as the only second-generation drug-eluting stent in Japan. Boston Scientific has already established a diversified product portfolio in the coronary intervention field, and we are committed to building on these leading treatment options for Japanese patients with coronary artery disease.”